Developer docs
API playgroundTry for free, no card

Search company profiles

Biotimize

Full company profile

uuid0002gtb

Namestring
Biotimize
Legal namestring
Biotimize
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Biotimize is a Brazilian biopharmaceutical Contract Development and Manufacturing Organization (CDMO) and the first of its kind operating in Brazil and South America. The company provides end-to-end development services from cell line development through analytical method validation, formulation, and non-clinical material production, serving biopharmaceutical companies, biotechnology startups, universities, research institutions, clinical research organizations, and government entities. Its technology platform spans mammalian cell expression (CHO cells achieving approximately 5 g/L recombinant protein), microbial systems (E. coli, yeast), and viral vector production, all built on single-use infrastructure at a GLP-certified facility in Piracicaba, São Paulo. Biotimize holds exclusive access in Brazil to Berkeley Lights' Beacon optofluidic platform, which reduces cell line development timelines from months to weeks.

The company generates revenue through project-based, quote-priced CDMO contracts covering pre-clinical and clinical-stage development work. Pricing is not publicly disclosed and is tailored to each project's scope, development stage, and partner requirements. The GLP-certified R&D Center (inaugurated March 2024) currently supports non-GMP services, while a 20,000+ m² GMP production facility is under construction to enable Phase 1-3 clinical and commercial batch production compliant with ANVISA, FDA, EMA, and TGA standards. Biotimize was established in partnership with Sthorm in early 2023 following a $30 million Series A round announced in September 2022. The company operates with 11-50 employees under founder-CEO Fernando Barbosa and is positioning itself to address the structural dependency of Brazil and Latin America on imported biologics by offering local infrastructure that can reduce development costs by up to 50% versus international CDMO alternatives.

Short descriptiontext

Biotimize is Brazil's first biopharmaceutical CDMO, offering end-to-end cell line development, process development, and analytical services to biopharma companies, biotech startups, universities, and government entities from its GLP-certified facility in Piracicaba, São Paulo.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPiracicaba, Brazil
HQ citystring
Piracicaba
HQ countrystring
Brazil
HQ regionstring
Latin America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharmaceutical CDMO services, cell line development, bioprocess engineering, contract manufacturing organization, biological drug development
Industry5 codes
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Contract Development and Manufacturing (CDMO)
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Development and Manufacturing Services
TypeProfessional Services
Description

Biotimize generates revenue through contracted CDMO services for biopharmaceutical development and manufacturing. Services include cell line development, process development (upstream/downstream), analytical testing, non-GMP and GMP production, and formulation development. Revenue is project-based with fees aligned to development stages from pre-clinical through clinical batch production.

biotimize.com.br
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Infrastructure, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1BTaas
Description

Biotimize's biotechnology as a service offering providing personalized bioprocess engineering-based services.

biotimize.com.br
Core offering1 text field

Biotimize operates as a Contract Development and Manufacturing Organization (CDMO) for biopharmaceuticals, providing personalized biotechnology and bioprocess engineering-based services. The company offers end-to-end production across bacteria, yeast, mammalian cells, and viral vectors, including cell line development, upstream and downstream process development, analytical method development, formulation, and non-clinical material production using single-use technology under GLP certification, with a GMP facility under construction.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Reduced development costs by up to 50%
+2 more records
Product and service2 records
1Biopharmaceutical CDMO Services (BTaas - Biotechnology as a Service)
CategoryContract Development and Manufacturing (CDMO)
Description

Contract Development and Manufacturing services for biopharmaceutical companies covering end-to-end production from cell line development through upstream and downstream process development, analytical method development and validation, formulation, and non-clinical material production across mammalian cells (CHO, ~5 g/L), bacteria (E. coli), yeast, and viral vectors, with single-use technology throughout production, purification, and fill-finish.

2GLP R&D Center Laboratory Services
CategoryGLP Laboratory and Pre-Clinical Development
Description

GLP-certified laboratory services for pre-clinical material production and translational development, providing the regulatory-grade basis for generating reliable pre-clinical data for submissions to ANVISA, FDA, EMA, and TGA. Targeted at universities, research institutions, biotechnology startups, and pharmaceutical companies needing pre-clinical and clinical-stage development infrastructure.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Partnership to develop conceptual, basic, and executive projects for the CDMO facility. PQE Group is an ISO 9001 certified technology solutions and compliance consulting services company with global capabilities. They are developing the complete facility design including R&D Center (GLP) and CDMO (GMP) in approximately 3,000 m² space.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership to strengthen Biotimize's mission and create bridges between Brazil and global innovation ecosystems. Together positioning Brazil as a developer and producer of advanced therapies rather than just a consumer, with focus on contributing solutions to Latin America and the Global South.

3PHP Biotech
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Development partnership for Pepcrotament, an innovative anticancer nanobody. Biotimize initiated production across bacteria, yeast, and mammalian cells to determine optimal expression platform. PHP Biotech's Chairman noted that working with a locally established entity enabled good communication and flexibility.

biotimize.com.br
4GTH-B (WHO Global Training Hub for Biomanufacturing)
Strategic tierMinorTypeOthers
Description

Participation in WHO's Global Training Hub for Biomanufacturing program held in South Korea. Biotimize researcher Bruna Campos attended the 2022 Introductory Training Course for Standard Practices (GxP), gaining knowledge in international quality standards for vaccine and biomedical product development.

biotimize.com.br
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Ecosystem partner listed as part of Biotimize's broader innovation network supporting the mission to strengthen Brazil's Health Economic-Industrial Complex.

6ViralCure
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Ecosystem partner in the Sthorm network focused on combining impact projects with strategic people aligned with democratizing access to science and health.

biotimize.com.br
Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global mammalian and microbial biologics CDMO leader offering end-to-end development and manufacturing services. Comparable as the benchmark full-service CDMO that Biotimize's end-to-end mammalian platform competes against for biotech and pharma customers.

TypeBroad incumbent
Description

Large diversified CDMO with biologics, cell therapy, and fill-finish capabilities. Comparable as an established incumbent offering overlapping biologics development and manufacturing services to global pharma customers.

TypeBroad incumbent
Description

China-based global biologics CDMO with end-to-end mammalian cell culture and viral vector services. Directly comparable in scope (CHO-based recombinant proteins, viral vectors, fill-finish) but at vastly greater scale and geographic reach.

TypeBroad incumbent
Description

Korean mega-CDMO with large-scale mammalian biologics manufacturing and recent viral vector expansion. Comparable end-to-end biologics CDMO positioning and similarly emerged from a regional base targeting global pharma clients.

TypeDirect peer
Description

Mammalian and microbial CDMO offering cell line development, process development, and GMP manufacturing. Closest comparable in modality mix (CHO/microbial/viral vectors) and end-to-end service model.

TypeDirect peer
Description

Germany-based CDMO focused on mammalian cell culture biologics, including cell line development and GMP production. Comparable mid-sized pure-play biologics CDMO with similar end-to-end service offering.

TypeBroad incumbent
Description

Global CRO/CDMO with biologics and cell therapy manufacturing services alongside discovery/preclinical offerings. Comparable as a broader life-sciences services platform with overlapping biopharmaceutical CDMO capabilities.

TypeRegional player
Description

Brazilian government-affiliated biomanufacturer producing vaccines and biologics for the public health system. Direct Brazilian comparable addressing the same localization gap, though focused on vaccines and government supply rather than commercial CDMO services.

TypeRegional player
Description

Major Brazilian pharmaceutical manufacturer with biologics and biosimilars activities. Comparable as a Brazilian-headquartered biopharma operator; appears as a Biotimize website partner and represents the type of regional customer Biotimize serves.

10Eurofarma
TypeRegional player
Description

Large Brazilian pharmaceutical company with growing biologics and biosimilars pipeline. Comparable as a LATAM-headquartered biopharma company that could anchor demand for Biotimize's CDMO services.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biotimize

Biopharmaceutical Contract Development and Manufacturing (CDMO)biotimize.com.br

Biotimize is Brazil's first biopharmaceutical CDMO, offering end-to-end cell line development, process development, and analytical services to biopharma companies, biotech startups, universities, and government entities from its GLP-certified facility in Piracicaba, São Paulo.

What Biotimize does

Biotimize is a Brazilian biopharmaceutical Contract Development and Manufacturing Organization (CDMO) and the first of its kind operating in Brazil and South America. The company provides end-to-end development services from cell line development through analytical method validation, formulation, and non-clinical material production, serving biopharmaceutical companies, biotechnology startups, universities, research institutions, clinical research organizations, and government entities. Its technology platform spans mammalian cell expression (CHO cells achieving approximately 5 g/L recombinant protein), microbial systems (E. coli, yeast), and viral vector production, all built on single-use infrastructure at a GLP-certified facility in Piracicaba, São Paulo. Biotimize holds exclusive access in Brazil to Berkeley Lights' Beacon optofluidic platform, which reduces cell line development timelines from months to weeks.

The company generates revenue through project-based, quote-priced CDMO contracts covering pre-clinical and clinical-stage development work. Pricing is not publicly disclosed and is tailored to each project's scope, development stage, and partner requirements. The GLP-certified R&D Center (inaugurated March 2024) currently supports non-GMP services, while a 20,000+ m² GMP production facility is under construction to enable Phase 1-3 clinical and commercial batch production compliant with ANVISA, FDA, EMA, and TGA standards. Biotimize was established in partnership with Sthorm in early 2023 following a $30 million Series A round announced in September 2022. The company operates with 11-50 employees under founder-CEO Fernando Barbosa and is positioning itself to address the structural dependency of Brazil and Latin America on imported biologics by offering local infrastructure that can reduce development costs by up to 50% versus international CDMO alternatives.

Biotimize firmographics

Firmographics
Name
Biotimize
Legal name
Biotimize
Website
https://biotimize.com.br
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
Biotimize is Brazil's first biopharmaceutical CDMO, offering end-to-end cell line development, process development, and analytical services to biopharma companies, biotech startups, universities, and government entities from its GLP-certified facility in Piracicaba, São Paulo.
Ownership category
akta.pro rank

Biotimize industry classification

Industry
Product category
Biopharmaceutical Contract Development and Manufacturing (CDMO)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Biopharmaceutical CDMO services
  • Cell line development
  • Bioprocess engineering
  • Contract manufacturing organization
  • Biological drug development

Where Biotimize is headquartered

Location

Headquarters

HQ city
Piracicaba
HQ country
Brazil
HQ region
Latin America

Offices2 records

Markets served

Biotimize business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Infrastructure, Personnel, Operations, Marketing or Sales

Revenue model

  1. Contract Development and Manufacturing Services: Biotimize generates revenue through contracted CDMO services for biopharmaceutical development and manufacturing. Services include cell line development, process development (upstream/downstream), analytical testing, non-GMP and GMP production, and formulation development. Revenue is project-based with fees aligned to development stages from pre-clinical through clinical batch production.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Biotimize product offering

Product offering

Core offering

Biotimize operates as a Contract Development and Manufacturing Organization (CDMO) for biopharmaceuticals, providing personalized biotechnology and bioprocess engineering-based services. The company offers end-to-end production across bacteria, yeast, mammalian cells, and viral vectors, including cell line development, upstream and downstream process development, analytical method development, formulation, and non-clinical material production using single-use technology under GLP certification, with a GMP facility under construction.

Differentiator

Problem solved

Functional benefit

Brands

  • BTaas: Biotimize's biotechnology as a service offering providing personalized bioprocess engineering-based services.

Products and services

  • Biopharmaceutical CDMO Services (BTaas - Biotechnology as a Service) Contract Development and Manufacturing services for biopharmaceutical companies covering end-to-end production from cell line development through upstream and downstream process development, analytical method development and validation, formulation, and non-clinical material production across mammalian cells (CHO, ~5 g/L), bacteria (E. coli), yeast, and viral vectors, with single-use technology throughout production, purification, and fill-finish.
  • GLP R&D Center Laboratory Services GLP-certified laboratory services for pre-clinical material production and translational development, providing the regulatory-grade basis for generating reliable pre-clinical data for submissions to ANVISA, FDA, EMA, and TGA. Targeted at universities, research institutions, biotechnology startups, and pharmaceutical companies needing pre-clinical and clinical-stage development infrastructure.

Quantifiable outcome

  • Reduced development costs by up to 50%
  • +2 more outcomes

Companies that use Biotimize

Customer profile

Named customers2 records

Segments5 records

Ideal customer profiles4 records

Biotimize technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Biotimize partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • PQE GroupcoreImplementation/ SI/ Consulting PartnerPartnership to develop conceptual, basic, and executive projects for the CDMO facility. PQE Group is an ISO 9001 certified technology solutions and compliance consulting services company with global capabilities. They are developing the complete facility design including R&D Center (GLP) and CDMO (GMP) in approximately 3,000 m² space.
  • Sail for HealthcoreStrategic or Co-development PartnerStrategic partnership to strengthen Biotimize's mission and create bridges between Brazil and global innovation ecosystems. Together positioning Brazil as a developer and producer of advanced therapies rather than just a consumer, with focus on contributing solutions to Latin America and the Global South.
  • PHP BiotechcoreStrategic or Co-development PartnerDevelopment partnership for Pepcrotament, an innovative anticancer nanobody. Biotimize initiated production across bacteria, yeast, and mammalian cells to determine optimal expression platform. PHP Biotech's Chairman noted that working with a locally established entity enabled good communication and flexibility.
  • GTH-B (WHO Global Training Hub for Biomanufacturing)minorOthersParticipation in WHO's Global Training Hub for Biomanufacturing program held in South Korea. Biotimize researcher Bruna Campos attended the 2022 Introductory Training Course for Standard Practices (GxP), gaining knowledge in international quality standards for vaccine and biomedical product development.
  • Clinergy HealthminorStrategic or Co-development PartnerEcosystem partner listed as part of Biotimize's broader innovation network supporting the mission to strengthen Brazil's Health Economic-Industrial Complex.
  • ViralCureminorStrategic or Co-development PartnerEcosystem partner in the Sthorm network focused on combining impact projects with strategic people aligned with democratizing access to science and health.

Scale indicators7 records

Recent moves10 records

Expansion highlights5 records

Biotimize competitors and assessment

Company assessment

Broad incumbents

  • Lonza Group: Global mammalian and microbial biologics CDMO leader offering end-to-end development and manufacturing services. Comparable as the benchmark full-service CDMO that Biotimize's end-to-end mammalian platform competes against for biotech and pharma customers.
  • Catalent: Large diversified CDMO with biologics, cell therapy, and fill-finish capabilities. Comparable as an established incumbent offering overlapping biologics development and manufacturing services to global pharma customers.
  • WuXi Biologics: China-based global biologics CDMO with end-to-end mammalian cell culture and viral vector services. Directly comparable in scope (CHO-based recombinant proteins, viral vectors, fill-finish) but at vastly greater scale and geographic reach.
  • Samsung Biologics: Korean mega-CDMO with large-scale mammalian biologics manufacturing and recent viral vector expansion. Comparable end-to-end biologics CDMO positioning and similarly emerged from a regional base targeting global pharma clients.
  • Charles River Laboratories: Global CRO/CDMO with biologics and cell therapy manufacturing services alongside discovery/preclinical offerings. Comparable as a broader life-sciences services platform with overlapping biopharmaceutical CDMO capabilities.

Direct peers

  • AGC Biologics: Mammalian and microbial CDMO offering cell line development, process development, and GMP manufacturing. Closest comparable in modality mix (CHO/microbial/viral vectors) and end-to-end service model.
  • Rentschler Biopharma: Germany-based CDMO focused on mammalian cell culture biologics, including cell line development and GMP production. Comparable mid-sized pure-play biologics CDMO with similar end-to-end service offering.

Regional players

  • Bio-Manguinhos / Fiocruz: Brazilian government-affiliated biomanufacturer producing vaccines and biologics for the public health system. Direct Brazilian comparable addressing the same localization gap, though focused on vaccines and government supply rather than commercial CDMO services.
  • Cristalia: Major Brazilian pharmaceutical manufacturer with biologics and biosimilars activities. Comparable as a Brazilian-headquartered biopharma operator; appears as a Biotimize website partner and represents the type of regional customer Biotimize serves.
  • Eurofarma: Large Brazilian pharmaceutical company with growing biologics and biosimilars pipeline. Comparable as a LATAM-headquartered biopharma company that could anchor demand for Biotimize's CDMO services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Biotimize social profiles

Digital presence

Biotimize financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biotimize leadership team

Management profile

Number of profiles

Profiles1 record

Biotimize funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biotimize M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biotimize

What does Biotimize do?

Biotimize operates as a Contract Development and Manufacturing Organization (CDMO) for biopharmaceuticals, providing personalized biotechnology and bioprocess engineering-based services. The company offers end-to-end production across bacteria, yeast, mammalian cells, and viral vectors, including cell line development, upstream and downstream process development, analytical method development, formulation, and non-clinical material production using single-use technology under GLP certification, with a GMP facility under construction.

Is Biotimize a public or private company?

Biotimize is a private company. It is classified as venture growth investor backed and is currently operating.

When was Biotimize founded?

Biotimize was founded in 2023. It employs 11 to 50 people.

Where is Biotimize based?

Biotimize is headquartered in Piracicaba, Brazil, in the Latin America region.

How does Biotimize make money?

One revenue line is on record: contract Development and Manufacturing Services.

Who are Biotimize's main competitors?

Broad incumbents on record are Lonza Group, Catalent, WuXi Biologics, Samsung Biologics and Charles River Laboratories. Direct peers are AGC Biologics and Rentschler Biopharma. Regional players are Bio-Manguinhos / Fiocruz, Cristalia and Eurofarma.

Does Biotimize have an API?

No public API is recorded for Biotimize.

What industry is Biotimize in?

Biotimize's product category is Biopharmaceutical Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals